Evolutionary Genomics Stock Three Year Return
| FNAM Stock | USD 0.0002 0.00 0.00% |
Fundamental analysis of Evolutionary Genomics allows traders to better anticipate movements in Evolutionary Genomics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Evolutionary |
Evolutionary Genomics Company Three Year Return Analysis
Evolutionary Genomics' Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
More About Three Year Return | All Equity Analysis
Three Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
| Competition |
Based on the latest financial disclosure, Evolutionary Genomics has a Three Year Return of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Evolutionary Three Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evolutionary Genomics' direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Evolutionary Genomics could also be used in its relative valuation, which is a method of valuing Evolutionary Genomics by comparing valuation metrics of similar companies.Evolutionary Genomics is currently under evaluation in three year return category among its peers.
Evolutionary Fundamentals
| Return On Equity | -145.27 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 9.18 M | |||
| Shares Outstanding | 6.66 M | |||
| Shares Owned By Insiders | 32.60 % | |||
| Price To Earning | (3.79) X | |||
| Price To Sales | 352.91 X | |||
| Gross Profit | (1.23 M) | |||
| EBITDA | (1.84 M) | |||
| Net Income | (2.79 M) | |||
| Cash And Equivalents | 897.78 K | |||
| Cash Per Share | 0.14 X | |||
| Total Debt | 3.74 M | |||
| Debt To Equity | 1.81 % | |||
| Current Ratio | 9.85 X | |||
| Book Value Per Share | (1.05) X | |||
| Cash Flow From Operations | (1.58 M) | |||
| Earnings Per Share | (0.53) X | |||
| Beta | -0.0153 | |||
| Market Capitalization | 4.66 M | |||
| Total Asset | 2.93 M | |||
| Retained Earnings | (1.33 M) | |||
| Working Capital | (12.68 K) | |||
| Current Asset | 991 | |||
| Current Liabilities | 13.67 K | |||
| Z Score | 0.6 | |||
| Net Asset | 2.93 M |
About Evolutionary Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evolutionary Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evolutionary Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evolutionary Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.